Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • FDA Approval granted...

    FDA Approval granted to Zydus Cadilla for Ahemdabad Plant

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2016-02-24T16:31:41+05:30  |  Updated On 24 Feb 2016 4:31 PM IST
    FDA Approval granted to Zydus Cadilla for Ahemdabad Plant
    Zydus Cadilla has announced its return to the US business market . Cadilla’s U.S. business was closed down in 2014, when the company was caught for malpractice of flouting FDA manufacturing standards.

    According to Fierce Pharma Manufacturing the Indian owner of Zydus Cadilla has announced the FDA permission given to the company to ship Doxycycline capsule in a Bombay Stock Exchange filing . The approval will see the company begin sending supplies of the medicine from its manufacturing facility in Ahmedabad.

    The first good news that the industrialist business man received was an FDA Establishment Inspection Report (EIR) for a plant in Himachal Pradesh last month, signaling the wrap up of the inspection of the unit by the FDA .

    The company now plans to expand business by increasing its range of products from this unit at Himachal Pradesh.

    After Cadilla received form 483s in the year 2014, for its key manufacturing unit in Moraiya near Ahemdabad and Zyfine API plant in the state, the industrialist has been under tremendous pressure. The seriousness of the two issues became apparent in FDA’s letter expressing anxious concerns about the Warfarin products in 2014. "These persistent failures indicate that your manufacturing process is not in a state of control." The letter made clear to him.

    Keen to get its unit back on operational track, the drug maker industrialist is working in close collaboration with the FDA. He has reiterated his commitment to bringing about the necessary changes to ensure quality product.

    Zydus Cadilla is one of the long list of Indian company’s on the FDA’s list for playing foul.
    Establishment Inspection ReportMoraiya plantUSFDAzyduszydus cadilla
    Source : with inputs from fierce pharma

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok